ClinicalTrials.gg
CompletedNCT01398475Updated Apr 21, 2017Results posted

A Relative Bioavailability and Food Effect Study of New Formulations

A Phase 1 interventional study of LY3009104 in Chronic Inflammatory Disorder and Arthritis, Rheumatoid, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-21.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
21st of 23
15 · median 290
Started
2011
with 1 other
Phase 1
Only one
of the 23
Registered
3rd of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 21st largest by enrollment, is one of 2 that started in 2011, is the only one in phase 1, and was the 3rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food. Safety evaluation and serial pharmacokinetic (PK) samples will be collected during each treatment period. Approximately 5 to 7 days of washout period between each treatment and a follow-up visit will occur approximately 5 to 7 days after the last dose of study drug.

03

Conditions studied

  • Chronic Inflammatory Disorder
  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males or females as determined by medical history and physical examination
  • Have a (BMI) of 18.5 to 29.9 kilograms per square meter (kg/m\^2), inclusive, at screening
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator
  • Have normal blood pressure and pulse rate as determined by the investigator
  • Have venous access sufficient to allow for blood sampling
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Have given written approved by Lilly and the ethical review board (ERB) governing the site

Male Participants:

  • Agree to use two forms of highly effective methods of [oral, injectable, or implanted hormonal contraceptives; condom with spermicidal foam/gel/film/cream/suppository; occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; intrauterine device; intrauterine system, for example, progestin releasing coil; and vasectomised male (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate)] with female partners of during the study and for at least 3 months following the last dose of study drug

Female participants:

  • Are women of non-childbearing potential, defined as: women with Mayer Rokitansky Kuster Hauser Syndrome (also referred to as Clinical Absence of Uterus and Vagina), or women who have had surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation), or women greater than 60 years of age, or women greater than 40 and less than 60 years of age who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential [FSH ≥40 milli-international units per milliliter (mIU/mL)]

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, or have completed or discontinued within the last 30 days from, a clinical trial involving an product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have a history of adverse drug reactions or "drug allergy" to more than 3 types of systemically administered medications (all penicillins and cephalosporins may be considered 1 type of medication for this purpose)
  • Are participants who have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY3009104
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Current or recent history (\<30 days prior to screening and/or \<45 days prior to Check-in) of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • Have an (ANC) less than 2000 cells per microliter (cell/μL). For abnormal values, a single repeat will be allowed
  • Have a history of, or current, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Regularly use known drugs of abuse
  • Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose
  • Have been exposed to a within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
  • Intend to use over-the-counter or prescription medication and herbal supplements within 14 days prior to dosing and during the study
  • Intend to use vitamins and mineral supplements within 2 days prior to dosing and during the study
  • Have donated blood of more than 450 milliliters (mL) within the previous 3 months
  • Have consumed grapefruit, starfruit, pomelos, or products containing these fruits, 7 days prior to the first dose and during the study
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption for 48 hours prior to admission in each period until the 48 hour PK sample has been collected [1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits]
  • Have used any tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to enrollment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    LY3009104 Reference Formulation

    8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.

    Drug: LY3009104

  • Experimental
    LY3009104 Test Formulation 1

    8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.

    Drug: LY3009104

  • Experimental
    LY3009104 Test Formulation 2

    8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.

    Drug: LY3009104

  • Experimental
    LY3009104 Test Formulation 2 + Meal

    8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.

    Drug: LY3009104

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Plasma Concentration-Time Curve (AUC)

    The area under the concentration-time curve from time 0 to infinity \[AUC(0-inf)\] is reported for participants who received either LY3009104 tablets or capsules in a fasted or fed state.

    Time frame: Predose up to 48 hours postdose for each of the 4 treatment periods

Secondary outcomes

  1. Pharmacokinetics: Maximum Plasma Concentration (Cmax)

    Time frame: Predose up to 48 hours postdose for each of the 4 treatment periods

  2. Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax)

    Time frame: Predose up to 48 hours postdose for each of the 4 treatment periods

07

Results

Posted Apr 21, 2017

Participant flow

Participant flow — Overall Study
MilestoneLY3009104 (LY) RF, LY 50-mcm Fed, LY 20-mcm, LY 50-mcm FastedLY 20-mcm, LY RF, LY 50-mcm Fasted, LY 50-mcm FedLY 50-mcm Fasted, LY 20-mcm, LY 50-mcm Fed, LY RFLY 50-mcm Fed, LY 50-mcm Fasted, LY RF, LY 20-mcm
Started4344
Received first intervention4344
Received second intervention4344
Received third intervention4344
Received fourth intervention4344
Completed4344
Not completed0000

Outcome measures

PrimaryPharmacokinetics: Plasma Concentration-Time Curve (AUC)

The area under the concentration-time curve from time 0 to infinity \[AUC(0-inf)\] is reported for participants who received either LY3009104 tablets or capsules in a fasted or fed state.

Time frame:
Predose up to 48 hours postdose for each of the 4 treatment periods
Reported as:
Geometric mean · nanomoles*hours per liter (nmol*h/L)
Pharmacokinetics: Plasma Concentration-Time Curve (AUC)
nanomoles*hours per liter (nmol*h/L)LY3009104 Reference FormulationLY3009104 Test Formulation 1 (20-mcm)LY3009104 Test Formulation 2 (50-mcm, Fed)LY3009104 Test Formulation 2 (50-mcm, Fasted)
Pharmacokinetics: Plasma Concentration-Time Curve (AUC)1670 ± 351710 ± 321510 ± 341700 ± 35
Statistical analysis
  • LY3009104 Reference Formulation vs LY3009104 Test Formulation 1 (20-mcm) · Geometric least squares (ls) mean ratio: 1.02 · 90% CI 0.951 to 1.10The geometric LS mean ratio (TF1 fasted divided by RF fasted) was calculated using a linear mixed-effects model adjusted for treatment, sequence, period, and participant.
  • LY3009104 Reference Formulation vs LY3009104 Test Formulation 2 (50-mcm, Fasted) · Geometric ls mean ratio: 1.02 · 90% CI 0.947 to 1.09The geometric LS mean ratio (TF2 fasted divided by RF fasted) was calculated using a linear mixed-effects model adjusted for treatment, sequence, period, and participant.
  • LY3009104 Test Formulation 2 (50-mcm, Fed) vs LY3009104 Test Formulation 2 (50-mcm, Fasted) · Geometric ls mean ratio: 0.888 · 90% CI 0.827 to 0.953The geometric LS mean ratio (TF2 fed divided by TF2 fasted) was calculated using a linear mixed-effects model adjusted for treatment, sequence, period, and participant.
SecondaryPharmacokinetics: Maximum Plasma Concentration (Cmax)
Time frame:
Predose up to 48 hours postdose for each of the 4 treatment periods
Reported as:
Geometric mean · nanomoles per liter (nmol/L)
Pharmacokinetics: Maximum Plasma Concentration (Cmax)
nanomoles per liter (nmol/L)LY3009104 Reference FormulationLY3009104 Test Formulation 1 (20-mcm)LY3009104 Test Formulation 2 (50-mcm, Fed)LY3009104 Test Formulation 2 (50-mcm, Fasted)
Pharmacokinetics: Maximum Plasma Concentration (Cmax)259 ± 26253 ± 19205 ± 27250 ± 30
Statistical analysis
  • LY3009104 Reference Formulation vs LY3009104 Test Formulation 1 (20-mcm) · Geometric least squares (ls) mean ratio: 0.979 · 90% CI 0.868 to 1.10The geometric LS mean ratio (TF1 fasted divided by RF fasted) was calculated using a linear mixed-effects model adjusted for treatment, sequence, period, and participant.
  • LY3009104 Reference Formulation vs LY3009104 Test Formulation 2 (50-mcm, Fasted) · Geometric ls mean ratio: 0.962 · 90% CI 0.852 to 1.08The geometric LS mean ratio (TF2 fasted divided by RF fasted) was calculated using a linear mixed-effects model adjusted for treatment, sequence, period, and participant.
  • LY3009104 Test Formulation 2 (50-mcm, Fed) vs LY3009104 Test Formulation 2 (50-mcm, Fasted) · Geometric ls mean ratio: 0.820 · 90% CI 0.727 to 0.925The geometric LS mean ratio (TF2 fed divided by TF2 fasted) was calculated using a linear mixed-effects model adjusted for treatment, sequence, period, and participant.
SecondaryPharmacokinetics: Time to Maximum Plasma Concentration (Tmax)
Time frame:
Predose up to 48 hours postdose for each of the 4 treatment periods
Reported as:
Median · hours (h)
Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax)
hours (h)LY3009104 Reference FormulationLY3009104 Test Formulation 1 (20-mcm)LY3009104 Test Formulation 2 (50-mcm, Fed)LY3009104 Test Formulation 2 (50-mcm, Fasted)
Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax)1.00 (0.50 to 3.00)1.00 (0.50 to 3.00)2.00 (1.00 to 4.00)1.00 (0.50 to 2.00)
Statistical analysis
  • LY3009104 Reference Formulation vs LY3009104 Test Formulation 1 (20-mcm) · Wilcoxon (Mann-Whitney) · p = 0.719 · Median difference (final values): 0 · 90% CI -0.250 to 0.500The median difference was calculated as TF1 fasted minus RF fasted.
  • LY3009104 Reference Formulation vs LY3009104 Test Formulation 2 (50-mcm, Fasted) · Wilcoxon (Mann-Whitney) · p = 0.960 · Median difference (final values): 0 · 90% CI -0.250 to 0.750The median difference was calculated as TF2 fasted minus RF fasted.
  • LY3009104 Test Formulation 2 (50-mcm, Fed) vs LY3009104 Test Formulation 2 (50-mcm, Fasted) · Wilcoxon (Mann-Whitney) · p = 0.006 · Median difference (final values): 0.500 · 90% CI 0 to 2.00The median difference was calculated as TF2 fed minus TF2 fasted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3009104 Reference Formulation—0/15 (0%)1/15 (6.7%)
LY3009104 Test Formulation 2 (50-mcm, Fed)—0/15 (0%)5/15 (33.3%)
LY3009104 Test Formulation 1 (20-mcm)—0/15 (0%)2/15 (13.3%)
LY3009104 Test Formulation 2 (50-mcm, Fasted)—0/15 (0%)2/15 (13.3%)
Most frequent other events
Most frequent other events
EventLY3009104 Reference FormulationLY3009104 Test Formulation 2 (50-mcm, Fed)LY3009104 Test Formulation 1 (20-mcm)LY3009104 Test Formulation 2 (50-mcm, Fasted)
Procedural site reactionInjury, poisoning and procedural complications0/152/150/151/15
GlossodyniaGastrointestinal disorders0/150/150/151/15
Mouth ulcerationGastrointestinal disorders0/150/150/151/15
Catheter site erythemaGeneral disorders1/151/151/150/15
Catheter site haematomaGeneral disorders0/151/151/150/15
Catheter site painGeneral disorders0/150/151/150/15
Catheter site pruritusGeneral disorders0/151/150/150/15
Vessel puncture site haematomaGeneral disorders0/151/150/150/15
CoughRespiratory, thoracic and mediastinal disorders0/151/150/150/15
Nasal congestionRespiratory, thoracic and mediastinal disorders0/151/150/150/15

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean38.0 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female1
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Entire Study Population
Asian14
White1
Region of Enrollment
Region of Enrollment(participants)Entire Study Population
Singapore15
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Singapore, 117597, Singapore
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2011
First posted
Jul 20, 2011
Start
Jul 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Apr 21, 2017
Last update
Apr 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01398475
Collaborators
Incyte Corporation
Responsible party
Sponsor
First posted
Jul 20, 2011
Start date
Jul 2011
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Apr 21, 2017
Last update
Apr 21, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion